Setara Biosciences raises $90 million to advance rare-disease pipeline after Actio spin-out

Actio Biosciences shipped its precision epilepsy drug to Jazz Pharmaceuticals and then separated the rest of its genetics-driven pipeline into a new company called Setara Biosciences.

Setara has secured $90 million in financing to continue developing therapies for rare diseases that were part of the original Actio portfolio.

The funding will allow Setara to advance its pipeline toward preclinical and early clinical studies, positioning the company as a focused player in the rare‑disease space.